There is consensus among the global health community that long-term collaboration in resilient biomanufacturing capacity and supply chains is needed to ensure the reliable delivery of health technologies such as vaccines, even during crisis conditions.
This paper highlights strategies that are essential to achieving this outcome, drawn from the experience of our company during the global pandemic response and looking forward to how governments and the private sector, including profit and not-for-profit private health actors, can most effectively work together to deliver healthcare post-pandemic. The strategies focus on vaccines, monoclonal antibodies, and new modalities manufactured by biotechnology companies and institutes.
